Volume 73, Issue 3, Pages (March 2018)

Slides:

Advertisements

Similar presentations

Volume 61, Issue 5, Pages (May 2012)

Advertisements

Volume 72, Issue 3, Pages (September 2017)

An Explanatory Case on the Limitations of Lymph Node Staging in Recurrent Prostate Cancer Marco Bandini, Giorgio Gandaglia, Nicola Fossati, Francesco.

Volume 68, Issue 6, Pages (December 2015)

Indications for Pelvic Nodal Treatment in Prostate Cancer Should Change. Validation of the Roach Formula in a Large Extended Nodal Dissection Series

Erectile Function Recovery After Nerve-Sparing Radical Prostatectomy for Prostate Cancer: Is Back to Baseline Status Enough for Patient Satisfaction?

Volume 62, Issue 3, Pages (September 2012)

Volume 155, Issue 3, Pages (March 1996)

The PSA Era is not Over for Prostate Cancer

Volume 59, Issue 2, Pages (February 2011)

European Urology Focus

Volume 50, Issue 1, Pages (July 2006)

Volume 58, Issue 4, Pages (October 2010)

Volume 47, Issue 4, Pages (April 2005)

Testosterone Therapy in Men With Prostate Cancer

The Effect of Other-cause Mortality Adjustment on Access to Alternative Treatment Modalities for Localized Prostate Cancer Among African American Patients

Volume 49, Issue 2, Pages (February 2006)

Volume 61, Issue 5, Pages (May 2012)

Volume 66, Issue 4, Pages (October 2014)

Volume 74, Issue 2, Pages (August 2018)

Volume 70, Issue 4, Pages (October 2016)

Volume 53, Issue 5, Pages (May 2008)

Increase in the Annual Rate of Newly Diagnosed Metastatic Prostate Cancer: A Contemporary Analysis of the Surveillance, Epidemiology and End Results Database

Volume 51, Issue 4, Pages (April 2007)

Volume 51, Issue 3, Pages (March 2007)

Who Benefits from Neoadjuvant or Adjuvant Hormone Therapy?

Volume 52, Issue 4, Pages (October 2007)

Volume 63, Issue 6, Pages (June 2013)

Volume 72, Issue 5, Pages (November 2017)

Volume 61, Issue 1, Pages (January 2012)

Volume 68, Issue 5, Pages (November 2015)

Volume 67, Issue 2, Pages (February 2015)

Volume 68, Issue 4, Pages (October 2015)

Volume 66, Issue 6, Pages (December 2014)

Volume 53, Issue 4, Pages (April 2008)

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Volume 74, Issue 2, Pages (August 2018)

Volume 62, Issue 1, Pages (July 2012)

Volume 67, Issue 3, Pages (March 2015)

Volume 64, Issue 5, Pages (November 2013)

Volume 71, Issue 5, Pages (May 2017)

Volume 61, Issue 3, Pages (March 2012)

The PSA Era is not Over for Prostate Cancer

Volume 61, Issue 5, Pages (May 2012)

Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases Axel Heidenreich, Nicola Fossati, David Pfister, Nazareno Suardi,

Volume 72, Issue 1, Pages (July 2017)

Volume 70, Issue 6, Pages (December 2016)

Volume 66, Issue 6, Pages (December 2014)

Volume 58, Issue 1, Pages 1-7 (July 2010)

The Inside-Out Transobturator Male Sling for the Surgical Treatment of Stress Urinary Incontinence After Radical Prostatectomy: Midterm Results of a Single-Center.

Volume 60, Issue 6, Pages (December 2011)

Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study Stephen H. Culp, Paul.

Prostate Cancer Nomograms: An Update

What's New in Prostate Cancer: Highlights from Urologic and Oncologic Congresses in 2006 Michel Soulié, Nicolas Mottet, Laurent Salomon, Jacques Irani,

Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy Matthew Mossanen, Kenneth.

The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Long-Term Hormonal Therapy: Who Would Benefit?

European Urology Oncology

European Urology Oncology

Trend of Adverse Stage Migration in Patients Treated with Radical Prostatectomy for Localized Prostate Cancer Felix Preisser, Michele Marchioni, Sebastiano.

European Urology Oncology

European Urology is “Your” Journal

Axel Heidenreich European Urology Supplements

Volume 54, Issue 1, Pages (July 2008)

Not All Multiparametric Magnetic Resonance Imaging–targeted Biopsies Are Equal: The Impact of the Type of Approach and Operator Expertise on the Detection.

Oncoforum Urology: Prostate Cancer 2008 at a Glance

Axel Heidenreich European Urology Supplements

Volume 51, Issue 5, Pages (May 2007)

European Urology Oncology

Presentation transcript:

Volume 73, Issue 3, Pages 436-444 (March 2018) Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy Nicola Fossati, R. Jeffrey Karnes, Michele Colicchia, Stephen A. Boorjian, Alberto Bossi, Thomas Seisen, Nadia Di Muzio, Cesare Cozzarini, Barbara Noris Chiorda, Claudio Fiorino, Giorgio Gandaglia, Paolo Dell’Oglio, Shahrokh F. Shariat, Gregor Goldner, Steven Joniau, Antonino Battaglia, Karin Haustermans, Gert De Meerleer, Valérie Fonteyne, Piet Ost, Hendrik Van Poppel, Thomas Wiegel, Francesco Montorsi, Alberto Briganti European Urology Volume 73, Issue 3, Pages 436-444 (March 2018) DOI: 10.1016/j.eururo.2017.07.026 Copyright © 2017 European Association of Urology Terms and Conditions

Fig. 1 A risk stratification tree assessing metastasis-free survival (MFS), based on 925 patients treated with salvage radiation therapy for prostate-specific antigen (PSA) rise after radical prostatectomy. European Urology 2018 73, 436-444DOI: (10.1016/j.eururo.2017.07.026) Copyright © 2017 European Association of Urology Terms and Conditions

Fig. 2 Probability of metastasis-free survival at 8 yr after radical prostatectomy (RP) plotted against the prostate-specific antigen (PSA) level at salvage treatment. Patients were stratified according to risk groups. SRT=salvage radiation therapy. European Urology 2018 73, 436-444DOI: (10.1016/j.eururo.2017.07.026) Copyright © 2017 European Association of Urology Terms and Conditions